Events calendar

Back to events
20
mar

Development of a New, Injectable COX-2 Analgesic to Reduce Opioid Use after Surgery

Tuesday March 20, 2018

18:30 - 21:00

Siboire Brewpub 5101 St Laurent Blvd Montreal, QC H2T 1R9 View Google Maps

BioTech Annecto Montreal is pleased to announce a presentation given by Damon Smith, PhD, CEO at Altus Formulation Inc entitled:

Development of a New, Injectable COX-2 Analgesic to Reduce Opioid Use after Surgery

Postoperative pain affects over 80% of people undergoing surgery and is too frequently treated with prolonged doses of opioids. Such strategies can lead to dependence and addiction.

We are using SmartCelle nanotechnology to develop a new formulation of the highly insoluble COX-2 inhibitor celecoxib (Celebrex®). SmartCelle, by increasing the solubility of celecoxib many thousands of times allows, for the first time, intravenous administration of this non-opioid drug. Red blood cell binding by SmartCelle technology also appears to significantly increase celecoxib circulation time permitting >12hr activity from a single injection. Such approaches are expected to reduce significantly the need for opioid analgesics after surgery thereby greatly enhancing patient experience and r

BioTech Annecto Montreal is pleased to announce a presentation given by Damon Smith, PhD, CEO at Altus Formulation Inc entitled:

Development of a New, Injectable COX-2 Analgesic to Reduce Opioid Use after Surgery

Postoperative pain affects over 80% of people undergoing surgery and is too frequently treated with prolonged doses of opioids. Such strategies can lead to dependence and addiction.

We are using SmartCelle nanotechnology to develop a new formulation of the highly insoluble COX-2 inhibitor celecoxib (Celebrex®). SmartCelle, by increasing the solubility of celecoxib many thousands of times allows, for the first time, intravenous administration of this non-opioid drug. Red blood cell binding by SmartCelle technology also appears to significantly increase celecoxib circulation time permitting >12hr activity from a single injection. Such approaches are expected to reduce significantly the need for opioid analgesics after surgery thereby greatly enhancing patient experience and reducing addiction potential. (http://altusformulation.com/)

Damon is a CEO and a founder member of the Altus team having worked for 10 years as Senior Vice President Research and Development at Labopharm Inc. Prior to joining Labopharm he spent time at Conjuchem, a Montreal start up, and prior to this was Executive Director of Development at Protherics, a UK based antibody development company listed on the London Stock Exchange.

Share this event: LinkedIn Twitter Email

Similar events

Submit an event

You want to share your event with members of the life sciences industry and health technology?

Fill out this form and we will be happy to add it to our calendar.

Submit an event
X

Subscribe to industry news

Which mailing list do you want to subscribe?

Flash InVivo
Info InVivo
Mailing list

What is your preferred language ?

French
English